The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease
Open accessAbstract
The association between nicotinic acetylcholine receptor (nAChR) dysfunction and cognitive decline in Alzheimer's disease (AD) has been widely exploited for its therapeutic potential. The effects of chronic nicotine exposure on Aβ accumulation have been studied in both humans and animal models, but its therapeutic efficacy for AD neuropathology is still unresolved. To date, no in vivo studies have addressed the consequences of activating nAChRs on tau pathology. To determine the effects of chronic nicotine administration on Aβ and tau pathology, we chronically administrated nicotine to a transgenic model of AD (3xTg-AD) in their drinking water. Here, we show that chronic nicotine intake causes an up-regulation of nicotinic receptors, which correlated with a marked increase in the aggregation and phosphorylation state of tau. These data show that nicotine exacerbates tau pathology in vivo . The increase in tau phosphorylation appears to be due to the activation of p38-mitogen-activated protein kinase, which is known to phosphorylate tau in vivo and in vitro . We also show that the 3xTg-AD mice have an age-dependent reduction of α7nAChRs compared with age-matched nontransgenic mice in specific brain regions. The reduction of α7nAChRs is first apparent at 6 months of age and is restricted to brain regions that show intraneuronal Aβ 42 accumulation. Finally, this study highlights the importance of testing compounds designed to ameliorate AD pathology in a model with both neuropathological lesions because of the differential effects it can have on either Aβ or tau.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated p38 activity is found in brains from patients with tauopathies (145–147) and in transgenic AD mice models expressing human tau (148–150) or mutant APP (151), both of which correlate with tau aggregation.”
From Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation (2011) · cites this paper as [150]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Self-citationSELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Asher, R. (1961) · The Lancet · doi:10.1016/s0140-6736(61)91217-x · Cited by 1,293
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease
Oddo, S. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.012 · Cited by 980
Self-citationFlores, C. M., Rogers, S. W., Pabreza, L. A., Wolfe, B. B., & Kellar, K. J. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08832-7 · Cited by 880
β-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High Affinity
Wang, H.-Y., Lee, D. H. S., D’Andrea, M. R., Peterson, P. A., Shank, R. P., & Reitz, A. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5626 · Cited by 818
Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780
Self-citationTau protein pathology in neurodegenerative diseases
Spillantini, M. G., & Goedert, M. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01337-x · Cited by 683
β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding
Busciglio, J., Lorenzo, A., Yeh, J., & Yankner, B. A. (1995) · Neuron · doi:10.1016/0896-6273(95)90232-5 · Cited by 595
Research works printed but not linked: 2
- Davies, P. & Maloney, A. J. (1976) Lancet 2, 1403.
- Flores, C. M., Rogers, S. W., Pabreza, L. A., Wolfe, B. B. & Kellar, K. J. (1992) Mol. Pharmacol. 41, 31-37.1732720
Cited by
Sorted by citations
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Self-citationBillings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.040 · Cited by 1,294
Self-citationThe cholinergic system in aging and neuronal degeneration
Schliebs, R., & Arendt, T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.058 · Cited by 1,047
Molecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid-β, and Tau
Caccamo, A., Majumder, S., Richardson, A., Strong, R., & Oddo, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100420 · Cited by 881
Self-citationThirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
Bertram, L., & Tanzi, R. E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2494 · Cited by 747
Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline
Ballinger, E. C., Ananth, M. R., Talmage, D. A., & Role, L. W. (2016) · Neuron · doi:10.1016/j.neuron.2016.09.006 · Cited by 763
Rajmohan, R., & Reddy, P. H. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160612 · Cited by 730
The Effects of Tobacco Smoke and Nicotine on Cognition and the Brain
Swan, G. E., & Lessov‐Schlaggar, C. N. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9035-9 · Cited by 605
The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease
Schliebs, R., & Arendt, T. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0579-2 · Cited by 548
Alzheimer's disease: Aβ, tau and synaptic dysfunction
LaFerla, F. M., & Oddo, S. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.02.009 · Cited by 477
Self-citationSmoking and increased Alzheimer's disease risk: A review of potential mechanisms
Durazzo, T. C., Mattsson, N., Weiner, M. W., & Initiative, A. D. N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.009 · Cited by 501
Muscarinic acetylcholine receptors as CNS drug targets
Langmead, C. J., Watson, J. M., & Reavill, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.009 · Cited by 413
Molecular Mechanisms of Amyloid Oligomers Toxicity
Kayed, R., & Lasagna‐Reeves, C. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129001 · Cited by 440
M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice
Caccamo, A., Oddo, S., Billings, L. M., Green, K. N., Martinez-Coria, H., Fisher, A., & LaFerla, F. M. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.020 · Cited by 417
Self-citationNatural products as a source of Alzheimer's drug leads
Williams, P., Sorribas, A., & Howes, M.-J. R. (2011) · Nat. Prod. Rep. · doi:10.1039/c0np00027b · Cited by 404
Majumder, S., Richardson, A., Strong, R., & Oddo, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025416 · Cited by 365
Self-citationAβ inhibits the proteasome and enhances amyloid and tau accumulation
Tseng, B. P., Green, K. N., Chan, J. L., Blurton-Jones, M., & LaFerla, F. M. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.014 · Cited by 384
Self-citationTemporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease
Oddo, S., Caccamo, A., Tran, L., Lambert, M. P., Glabe, C. G., Klein, W. L., & LaFerla, F. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507892200 · Cited by 379
Self-citationShi, J., Guan, J., Jiang, B., Brenner, D. A., del Monte, F., Ward, J. E., Connors, L. H., Sawyer, D. B., Semigran, M. J., MacGillivray, T. E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912263107 · Cited by 342
Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment.
Lombardo, S., & Maskos, U. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.11.018 · Cited by 281
The role of G protein-coupled receptors in the pathology of Alzheimer's disease
Thathiah, A., & De Strooper, B. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2977 · Cited by 288
Oddo, S., Vasilevko, V., Caccamo, A., Kitazawa, M., Cribbs, D. H., & LaFerla, F. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608485200 · Cited by 298
Self-citationBitanihirwe, B. K. Y., & Cunningham, M. G. (2009) · Synapse · doi:10.1002/syn.20683 · Cited by 268
A Dynamic Relationship between Intracellular and Extracellular Pools of Aβ
Oddo, S., Caccamo, A., Smith, I. F., Green, K. N., & LaFerla, F. M. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050593 · Cited by 261
Self-citationModifiable Risk Factors for Alzheimer’s Disease
Edwards III, G. A., Gamez, N., Escobedo Jr., G., Calderon, O., & Moreno-Gonzalez, I. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00146 · Cited by 253
Mastrangelo, M. A., & Bowers, W. J. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-81 · Cited by 242
Giménez‐Llort, L., Blázquez, G., Cañete, T., Johansson, B. A., Oddo, S., Tobeña, A., LaFerla, F. M., & Fernández‐Teruel, A. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2006.07.007 · Cited by 246
Self-citationCaccamo, A., Oddo, S., Tran, L. X., & LaFerla, F. M. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.061178 · Cited by 227
Self-citationLiu, Z., Jiang, M., Kang, T., Miao, D., Gu, G., Song, Q., Yao, L., Hu, Q., Tu, Y., Pang, Z., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.003 · Cited by 219
Smoking, nicotine and neuropsychiatric disorders
Döme, P., Lazáry, J., Kalapos, M. P., & Rihmer, Z. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.07.013 · Cited by 227
Memantine Improves Cognition and Reduces Alzheimer’s-Like Neuropathology in Transgenic Mice
Martínez‐Coria, H., Green, K. N., Billings, L. M., Kitazawa, M., Albrecht, M., Rammes, G., Parsons, C. G., Gupta, S., Banerjee, P., & LaFerla, F. M. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090452 · Cited by 224
Self-citationPicciotto, M. R. (2007) · Frontiers in bioscience · doi:10.2741/2695 · Cited by 212
Role of Vascular Risk Factors and Vascular Dysfunction in Alzheimer's Disease
Dickstein, D. L., Walsh, J., Brautigam, H., Stockton, S. D., Gandy, S., & Hof, P. R. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20155 · Cited by 155
Brain Imaging of Nicotinic Receptors in Alzheimer's Disease
Wu, J., Ishikawa, M., Zhang, J., & Hashimoto, K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/548913 · Cited by 211
The Cholinergic System, the Adrenergic System and the Neuropathology of Alzheimer’s Disease
Bekdash, R. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031273 · Cited by 222
Medina, D. X., Caccamo, A., & Oddo, S. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00430.x · Cited by 200
Self-citationReimagining cholinergic therapy for Alzheimer’s disease
Giacobini, E., Cuello, A. C., & Fisher, A. (2022) · Brain · doi:10.1093/brain/awac096 · Cited by 187
Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease
Pákáski, M., & Kalman, J. L. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.06.005 · Cited by 191
Amyloid Beta: Multiple Mechanisms of Toxicity and Only Some Protective Effects?
Carrillo‐Mora, P., Luna, R., & Colín-Barenque, L. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/795375 · Cited by 187
Chang, K., Chang, M., Muo, C., Wu, T.-N., Chen, C., & Kao, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103078 · Cited by 171
Impaired Attention in the 3xTgAD Mouse Model of Alzheimer's Disease: Rescue by Donepezil (Aricept)
Romberg, C., Mattson, M. P., Mughal, M. R., Bussey, T. J., & Saksida, L. M. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.5242-10.2011 · Cited by 160
Is Alzheimer’s Disease Risk Modifiable?
Serrano‐Pozo, A., & Growdon, J. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad181028 · Cited by 169
Fisher, A. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.002 · Cited by 151
Fisher, A. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07507.x · Cited by 140
Learning Decreases Aβ*56 and Tau Pathology and Ameliorates Behavioral Decline in 3xTg-AD Mice
Billings, L. M., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4800-06.2007 · Cited by 145
Self-citationMechanisms Behind the Neuroprotective Actions of Cholinesterase Inhibitors in Alzheimer Disease
Nordberg, A. K. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213804.59187.2d · Cited by 134
Cigarette Smoking Accelerated Brain Aging and Induced Pre-Alzheimer-Like Neuropathology in Rats
Ho, J. Y. S., Yang, X., Yeung, S., Chiu, K., Lau, C. G., Tsang, A. W.-T., Mak, J., & Chang, R. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036752 · Cited by 138
The role of nicotinic acetylcholine receptors in Alzheimer’s disease
Oddo, S., & LaFerla, F. M. (2006) · Journal of Physiology-Paris · doi:10.1016/j.jphysparis.2005.12.080 · Cited by 132
Self-citationNicotine: specific role in angiogenesis, proliferation and apoptosis
Cardinale, A., Nastrucci, C., Cesario, A., & Russo, P. (2011) · Critical Reviews in Toxicology · doi:10.3109/10408444.2011.623150 · Cited by 126
Oddo, S., Caccamo, A., Tseng, B., Cheng, D., Vasilevko, V., Cribbs, D. H., & LaFerla, F. M. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.2464-08.2008 · Cited by 125
Self-citationAssociation between Bone Mineral Density and the Risk of Alzheimer's Disease
Zhou, R., Deng, J., Zhang, M., Zhou, H.-D., & Wang, Y.-J. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101467 · Cited by 123
Smoking exacerbates amyloid pathology in a mouse model of Alzheimer’s disease
Moreno‐González, I., Estrada, L. D., Sánchez‐Mejías, E., & Soto, C. A. (2013) · Nature Communications · doi:10.1038/ncomms2494 · Cited by 132
Ambegaokar, S. S., & Jackson, G. R. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr432 · Cited by 113
Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
Libro, R., Giacoppo, S., Soundara Rajan, T., Bramanti, P., & Mazzon, E. (2016) · Molecules · doi:10.3390/molecules21040518 · Cited by 107
The Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer′s Disease (AD)
Mroczko, B., Groblewska, M., & Litman‐Zawadzka, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194661 · Cited by 111
Schaeffer, E. L., & Gattaz, W. F. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1092-0 · Cited by 98
Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
Mroczko, B., Groblewska, M., Litman-Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071884 · Cited by 97
Chang, K., Chung, C., Lin, C., Sung, F., Wu, T.-N., & Kao, C. (2013) · AGE · doi:10.1007/s11357-013-9608-x · Cited by 96
Edrey, Y. H., Medina, D. X., Gaczynska, M. E., Osmulski, P. A., Oddo, S., Caccamo, A., & Buffenstein, R. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.03.032 · Cited by 95
Self-citationParachikova, A., Green, K. N., Hendrix, C., & LaFerla, F. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014015 · Cited by 87
Self-citationStatins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
Boimel, M., Grigoriadis, N., Lourbopoulos, A., Touloumi, O., Rosenmann, D., Abramsky, O., & Rosenmann, H. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31819ac3cb · Cited by 86
Pogocki, D., Ruman, T., Danilczuk, M., Danilczuk, M., Celuch, M., & Wałajtys-Rode, E. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.02.038 · Cited by 84
Geerts, H., & Grossberg, G. T. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006288734 · Cited by 88
Autoimmune Manifestations in the 3xTg-AD Model of Alzheimer's Disease
Marchese, M., Cowan, D., Head, E., Ma, D., Karimi, K., Ashthorpe, V., Kapadia, M., Zhao, H., Davis, P., & Sakic, B. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131490 · Cited by 94
Medeiros, R., Castello, N. A., Cheng, D., Kitazawa, M., Baglietto‐Vargas, D., Green, K. N., Esbenshade, T. A., Bitner, R. S., Decker, M. W., & LaFerla, F. M. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.10.010 · Cited by 83
Self-citationGiménez-Llort, L., Arranz, L., Maté, I., & De la Fuente, M. (2008) · Neuroimmunomodulation · doi:10.1159/000156475 · Cited by 91
β-Arrestin1 regulates γ-secretase complex assembly and modulates amyloid-β pathology
Liu, X., Zhao, X., Zeng, X., Bossers, K., Swaab, D. F., Zhao, J., & Pei, G. (2012) · Cell Research · doi:10.1038/cr.2012.167 · Cited by 81
Oddo, S., Caccamo, A., Cheng, D., Jouleh, B., Torp, R., & LaFerla, F. M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04607.x · Cited by 79
Self-citationIncreased Hippocampal Excitability in the 3xTgAD Mouse Model for Alzheimer's Disease In Vivo
Davis, K. E., Fox, S., & Gigg, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091203 · Cited by 72
Ca2+ Dyshomeostasis Disrupts Neuronal and Synaptic Function in Alzheimer’s Disease
McDaid, J., Mustaly-Kalimi, S., & Stutzmann, G. E. (2020) · Cells · doi:10.3390/cells9122655 · Cited by 73
Kelly, T. D. (2007) · Frontiers in bioscience · doi:10.2741/2445 · Cited by 72
Kem, W. R., Soti, F. S., Wildeboer, K. M., LeFrancois, S., MacDougall, K., Wei, D., Chou, K., & Arias, H. R. (2006) · Marine Drugs · doi:10.3390/md403255 · Cited by 72
Bitner, R., Nikkel, A., Markosyan, S., Otte, S., Puttfarcken, P., & Gopalakrishnan, M. (2009) · Brain Research · doi:10.1016/j.brainres.2009.01.069 · Cited by 72
Bedse, G., Romano, A., Cianci, S., Lavecchia, A. M., Pace, L., Elphick, M. R., LaFerla, F. M., Vendemiale, G., Grillo, C., Fabio Altieri, F., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131910 · Cited by 69
Self-citationRole of GSK‐3β activation and α7 nAChRs in Aβ1–42‐induced tau phosphorylation in PC12 cells
Hu, M., Waring, J. F., Gopalakrishnan, M., & Li, J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05483.x · Cited by 67
Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Walker, D., & Lue, L.-F. (2007) · Current Neuropharmacology · doi:10.2174/157015907782793667 · Cited by 66
Neuronal nicotinic acetylcholine receptor–cholesterol crosstalk in Alzheimer's disease
Barrantes, F. J., Borroni, V., & Vallés, S. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.11.036 · Cited by 66
Animal Models of Metabolic Disorders in the Study of Neurodegenerative Diseases: An Overview
Bem, A. F. D., Krolow, R., Farias, H. R., de Rezende, V. L., Gelain, D. P., Moreira, J. C. F., Duarte, J. M. N., & de Oliveira, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.604150 · Cited by 69
G Protein–Coupled Receptors, Cholinergic Dysfunction, and Aβ Toxicity in Alzheimer’s Disease
Thathiah, A., & Strooper, B. D. (2009) · Science Signaling · doi:10.1126/scisignal.293re8 · Cited by 59
Ahmed, T., Zahid, S., Mahboob, A., & Farhat, S. M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160325121145 · Cited by 60
Vallés, A. S., Borroni, M., & Barrantes, F. (2014) · CNS Drugs · doi:10.1007/s40263-014-0201-3 · Cited by 55
Neuropathology of cigarette smoking
Chang, R. C., Ho, J. Y. S., Wong, C. S., Gentleman, S. M., & Ng, H. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1210-x · Cited by 59
Neuronal receptors as targets for the action of amyloid-beta protein (Aβ) in the brain
Patel, A. N., & Jhamandas, J. H. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002134 · Cited by 51
Giménez‐Llort, L., Maté, I., Manassra, R., Vida, C., & la Fuente, M. D. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06639.x · Cited by 53
Nicotine-induced memory impairment by increasing brain oxidative stress
Hriţcu, L., Ciobica, A. S., & Gorgan, L. (2009) · Open Life Sciences · doi:10.2478/s11535-009-0029-x · Cited by 48
Lista, S., Vergallo, A., Teipel, S. J., Lemercier, P., Giorgi, F. S., Gabelle, A., Garaci, F., Mercuri, N. B., Babiloni, C., Gaire, B. P., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101819 · Cited by 47
Dong, Y., Bi, W., Zheng, K., Zhu, E., Wang, S., Xiong, Y., Chang, J., Jiang, J., Liu, B., Lu, Z., et al. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.557647 · Cited by 45
Davis, K. E., Burnett, K., & Gigg, J. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.05.005 · Cited by 45
Gene-Environment Interaction Research and Transgenic Mouse Models of Alzheimer's Disease (Erratum)
Chouliaras, L., Sierksma, A. S. R., Kenis, G., Prickaerts, J., Lemmens, M. A. M., Brasnjevic, I., van Donkelaar, E. L., Martínez‐Martínez, P., Losen, M. H., Baets, M. H. D., et al. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/356862 · Cited by 44
Arranz, L., Castro, N. M. D., Baeza, I., Giménez‐Llort, L., & la Fuente, M. D. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110236 · Cited by 44
Bencherif, M. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.37 · Cited by 44
Ren, K., Thinschmidt, J. S., Liu, J., Ai, L., Papke, R. L., King, M. A., Hughes, J. A., & Meyer, E. M. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.11.023 · Cited by 42
Cholinergic Mechanisms in the Cerebral Cortex
Ovsepian, S. V., O’Leary, V. B., & Záborszky, L. (2015) · The Neuroscientist · doi:10.1177/1073858415588264 · Cited by 39
Oxidative damage and amyloid‐β metabolism in brain regions of the longest‐lived rodents
Edrey, Y. H., Oddo, S., Cornelius, C., Caccamo, A., Calabrese, V., & Buffenstein, R. (2013) · Journal of Neuroscience Research · doi:10.1002/jnr.23320 · Cited by 41
Self-citationTropea, M. R., Puma, D. D. L., Melone, M., Gulisano, W., Arancio, O., Grassi, C., Conti, F., & Puzzo, D. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102154 · Cited by 42
The pathophysiology of traumatic brain injury in α7 nicotinic cholinergic receptor knockout mice
Kelso, M. L., Wehner, J. M., Collins, A. C., Scheff, S. W., & Pauly, J. R. (2006) · Brain Research · doi:10.1016/j.brainres.2006.01.127 · Cited by 37
Profile for Amyloid-β and Tau Expression in Primary Cortical Cultures from 3xTg-AD Mice
Vale, C., Alonso, E., Rubiolo, J. A., Vieytes, M. R., LaFerla, F. M., Giménez‐Llort, L., & Botana, L. M. (2009) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-009-9482-3 · Cited by 37
Self-citationLace, G., Wharton, S. B., & Ince, P. G. (2007) · Clinical Neuropathology · doi:10.5414/npp26043 · Cited by 37
Vallés, A. S., & Barrantes, F. J. (2023) · Cells · doi:10.3390/cells12162051 · Cited by 37
Deng, J., Shen, C., Wang, Y., Zhang, M., Li, J., Xu, Z., Gao, C., Fang, C., & Zhou, H. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.03.029 · Cited by 36
Metadata
- Authors
- Oddo, S., Caccamo, A., Green, K. N., Liang, K., Tran, L., Chen, Y., Leslie, F. M., & LaFerla, F. M.
- Affiliations
- University of California, Irvine (US)
- Departments of Neurobiology and Behavior and Pharmacology, University of California, Irvine, CA 92697
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2005-02-10
- Volume
- 102
- Issue
- 8
- Pages
- 3046-3051
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC549455
- OpenAlex
- W2139557860
- Cited by
- 211
- References
- 47
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 9 · 2023: 7 · 2022: 7 · 2021: 6 · 2020: 6 · 2019: 7 · 2018: 6 · 2017: 5 · 2016: 8 · 2015: 5 · 2014: 14 · 2013: 14 · 2012: 11
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- National Institute on Aging (AG0212982)
- National Institute on Drug Abuse (DA-10612, R01DA010612)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- chronic nicotine administration, tau pathology, Alzheimer's disease, nicotinic acetylcholine receptors, alpha7 nicotinic acetylcholine receptor, tau phosphorylation, p38 MAPK, amyloid-beta deposition, 3xTg-AD mice
- MeSH terms
- Age Factors, Alzheimer Disease, Animals, Calcium, Disease Models, Animal, Mice, Transgenic, Nicotine, Phosphorylation, Receptors, Nicotinic, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, tau Proteins, Mice, alpha7 Nicotinic Acetylcholine Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
